Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BEBT-908 Plus CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL), and to Explore the Relationship Between Tumor Biomarkers and the Efficacy and Safety of BEBT-908 Plus CHOP.

NCT07676175 is registered in ClinicalTrials.gov with BeBetter Med Inc as lead sponsor.

NCT NCT07676175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07676175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BEBT-908 Plus CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL), and to Explore the Relationship Between Tumor Biomarkers and the Efficacy and Safety of BEBT-908 Plus CHOP.
Lead sponsor
BeBetter Med Inc
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
June 30, 2028
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

previously untreated peripheral t-cell lymphoma